Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 2

1(12.5%)

Phase 3

1(12.5%)

8Total

Phase 1(6)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06797986Phase 1Not Yet Recruiting

A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.

Role: lead

NCT05993325Phase 3Active Not Recruiting

Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers

Role: lead

NCT05576623Phase 1Completed

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine

Role: lead

NCT05047692Phase 1Completed

Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers

Role: lead

NCT04666012Phase 1Completed

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers

Role: lead

NCT05520970Phase 2Terminated

Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1

Role: lead

NCT02866006Phase 1Completed

Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

Role: lead

NCT03425773Phase 1Completed

Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care

Role: lead

All 8 trials loaded